Summary of Purpose
This study will determine the safety and effectiveness of the drug Replagal for treating people with Fabry disease, an inherited metabolic disorder. In this disease, an enzyme called alpha-galactosidase A, which normally breaks down a lipid (fatty substance) known as ceramidetrihexoside, is missing or does not function properly. As a result, the lipid accumulates in the body, causing problems with the kidneys,...Read More →
The following dates are available for this trial. Trial information last updated on 3 March 2008.
|1 Nov 2004||30 Nov 2004||Unavailable||1 Dec 2005||1 Dec 2005||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Purpose: Treatment